StockData
Revolution Medicines, Inc. logo

Revolution Medicines, Inc. (RVMD) shareholders

RVMDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as RVMDW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 3/30
$162.69−4.18 (-2.50%)

Close on Nov 17, 2026Market cap $34.87BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
214M
Shares held, 13F filers
Institutional holders
690
243 new, 62 sold out
Net institutional buying
25M
In Q2 2026
Insider trades, 12 months
0 buys · 166 sales
Net sold $155.00M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Abigail P. Johnson
Joint filing with FMR LLC (7.20%)
15,402,1037.20%13G (passive) amendmentSep 30, 2026
Luo Patrick (Cheng)
Joint filing with Wehrly, Mark C. (7.50%), Dreyfuss, Philip D. (7.50%) and 13 more
14,596,1497.50%13G (passive) amendmentDec 31, 2025
Kim, David T.
Joint filing with Dapice Joshua J. (6.40%), Dreyfuss, Philip D. (6.40%) and 13 more
13,564,1496.40%13G (passive) amendmentJun 30, 2026
Fried, Richard B
Joint filing with Wehrly, Mark C. (7.90%), Dreyfuss, Philip D. (7.90%) and 15 more
13,262,0457.90%13G (passive) amendmentDec 31, 2024
BlackRock, Inc.12,201,3955.70%13G (passive)Jun 30, 2026
Baker Bros. Advisors (GP) LLC
Joint filing with Baker Bros. Advisors LP (5.30%), Felix J. Baker (5.30%) and 1 more
11,443,3575.30%13G (passive)Jun 30, 2026
Saito Edric C.
Joint filing with Wehrly, Mark C. (6.80%), Dreyfuss, Philip D. (6.80%) and 14 more
11,331,0456.80%13G (passive) amendmentSep 30, 2024
Vanguard Capital Management10,999,0445.13%13G (passive)Sep 30, 2026
JANUS HENDERSON GROUP Ltd.10,736,1455.10%13G (passive)Jun 30, 2026
Wellington Management Group LLP
Joint filing with Wellington Group Holdings LLP (5.50%), Wellington Investment Advisors Holdings LLP (5.50%) and 1 more
10,259,7385.50%13G (passive) amendmentJun 30, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of RVMDValueChange% of portfolio
BlackRock, Inc.13,695,790–$2.56B+2,483,0840.04%
Farallon Capital Management LLC13,550,796–$2.54B−54,00011.71%
FMR LLC12,200,422–$2.28B+3,736,1080.10%
Baker Bros. Advisors LP11,443,357–$2.14B+1,888,00010.74%
Jupiter Topco LLC10,736,145–$2.01BNew0.82%
Darwin Global Management, Ltd.10,629,822–$2.05B+8,418,80454.45%
Vanguard Capital Management LLC9,088,661–$1.70B+726,3770.04%
Vanguard Portfolio Management LLC8,294,855–$1.55B+792,2320.07%
Nextech Invest, Ltd.7,601,087–$1.42B–67.55%
Paradigm Biocapital Advisors LP6,361,323–$1.19B−294,38022.31%
UBS Group AG5,448,364–$1.02B+1,061,5730.13%
State Street Corp4,897,051–$917.12M+494,3890.03%
Capital World Investors4,008,244–$750.66MNew0.09%
Geode Capital Management, LLC3,942,676–$736.81M+604,5340.04%
Wellington Management Group Llp3,843,415–$719.79M−2,184,4040.12%
JPMorgan Chase & Co3,298,066–$636.93M+2,996,6730.04%
Bvf Inc/Il2,965,160–$555.32M+108,37814.20%
Alphabet Inc.2,946,619–$551.84M−345,9060.56%
Casdin Capital, LLC2,577,333–$482.68M–24.16%
Deerfield Management Company, L.P. (Series C)2,392,000–$447.97M+95,0004.67%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares heldNew / addedReduced / closedShares boughtShares sold
Q2 2026690214M243 / 241148 / 6257M32M
Q1 2026514199M172 / 165127 / 3948M34M
Q4 2025387201M107 / 136101 / 3830M24M
Q3 2025323194M64 / 11991 / 4519M15M
Q2 2025308191M58 / 11491 / 3320M22M
Q1 2025284193M50 / 9689 / 4123M13M
Q4 2024281193M62 / 12359 / 3033M14M
Q3 2024255175M56 / 9165 / 2129M13M
Q2 2024223173M40 / 8360 / 2518M11M
Q1 2024210166M50 / 5665 / 2416M16M
Q4 2023184166M54 / 8134 / 3667M14M
Q3 2023168112M42 / 6039 / 1310M9M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

492 funds held RVMD in Q2 2026, 45% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of RVMDValue% of fundAs of
Vanguard Total Stock Market Index Fund6,412,413–$1.20B0.05%Jun 30, 2026
Vanguard Small-Cap Index Fund4,631,150–$867.32M0.46%Jun 30, 2026
Vanguard Small-Cap Growth Index Fund2,670,853–$500.20M1.06%Jun 30, 2026
Fidelity Growth Company Fund2,475,942–$389.91M0.39%May 31, 2026
Vanguard Extended Market Index Fund2,291,511–$429.15M0.44%Jun 30, 2026
Vanguard Health Care Fund1,988,729–$372.95M0.98%Jul 31, 2026
Growth Fund of America1,838,422–$289.51M0.08%May 31, 2026
iShares Biotechnology ETF1,349,118–$252.66M2.78%Jun 30, 2026
JPMorgan Large Cap Growth Fund1,166,558–$218.47M0.18%Jun 30, 2026
iShares Russell Mid-Cap Growth ETF1,128,977–$211.43M0.98%Jun 30, 2026
Fidelity Extended Market Index Fund1,011,551–$159.30M0.37%May 31, 2026
Fidelity OTC Portfolio1,002,878–$188.07M0.44%Jul 31, 2026
Janus Henderson Enterprise Fund978,312–$183.22M0.82%Jun 30, 2026
Schwab U.S. Small-Cap ETF942,767–$148.47M0.65%May 31, 2026
Janus Henderson Forty Fund937,887–$175.65M0.74%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares ownedLatest filing
Mark A. GoldsmithSee Remarks, Director314,766Sep 18, 2026
Jack AndersChief Financial Officer119,216Nov 13, 2026
Anthony ManciniSee Remarks39,765Nov 12, 2026
Alan B. SandlerChief Development Officer52,559Oct 1, 2026
Jeff CisliniSVP & General Counsel51,776Sep 29, 2026
Margaret A. HornChief Operating Officer154,571Sep 18, 2026
Stephen Michael KelseySee Remarks286,307Sep 18, 2026
Xiaolin WangSee Remarks116,063Mar 19, 2026
Lin WeiChief Medical Officer101,366Mar 19, 2026
Flavia BorelliniDirector28,715Nov 17, 2026
Alexis BorisyDirector2,329,450Nov 13, 2026
Elizabeth M. AndersonDirector31,423Sep 24, 2026
Lorence H. KimDirector10,136Sep 10, 2026
Sushil PatelDirector24,078Jul 1, 2026
Sandra HorningDirector97,765Jun 23, 2026
Frank ClyburnDirector10,929Jun 23, 2026
Thilo SchroederDirector7,601,087Dec 9, 2024

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Flavia Borellini
Director
Nov 13, 2026Option exercise+2,500$37.54$93.85K28,715
Alexis Borisy
Director
Nov 11, 2026Gift−10,625––2,329,450
Jack Anders
Chief Financial Officer
Nov 11, 2026Sale(10b5-1 plan)−9,889$192.84$1.91M119,216
Jack Anders
Chief Financial Officer
Nov 11, 2026Sale(10b5-1 plan)−9,486$191.94$1.82M129,105
Jack Anders
Chief Financial Officer
Nov 11, 2026Sale(10b5-1 plan)−500$190.99$95.50K138,591
Jack Anders
Chief Financial Officer
Nov 11, 2026Sale(10b5-1 plan)−200$189.17$37.83K139,091
Jack Anders
Chief Financial Officer
Nov 11, 2026Sale(10b5-1 plan)−600$187.34$112.40K139,291
Jack Anders
Chief Financial Officer
Nov 11, 2026Sale(10b5-1 plan)−400$186.41$74.57K139,891
Jack Anders
Chief Financial Officer
Nov 11, 2026Sale(10b5-1 plan)−800$185.04$148.03K140,291
Jack Anders
Chief Financial Officer
Nov 11, 2026Sale(10b5-1 plan)−1,900$184.02$349.65K141,091
Jack Anders
Chief Financial Officer
Nov 11, 2026Sale(10b5-1 plan)−2,700$182.87$493.75K142,991
Jack Anders
Chief Financial Officer
Nov 11, 2026Sale(10b5-1 plan)−5,776$182.09$1.05M145,691
Jack Anders
Chief Financial Officer
Nov 11, 2026Sale(10b5-1 plan)−3,499$181.04$633.47K151,467
Jack Anders
Chief Financial Officer
Nov 11, 2026Option exercise+19,850$18.56$368.42K154,966
Jack Anders
Chief Financial Officer
Nov 11, 2026Option exercise+15,900$42.45$674.96K135,116
Anthony Mancini
See Remarks
Nov 9, 2026Sale(10b5-1 plan)−811$200.00$162.20K39,765
Anthony Mancini
See Remarks
Nov 9, 2026Option exercise+1$102.02$10240,576
Anthony Mancini
See Remarks
Nov 9, 2026Option exercise+810$33.62$27.23K40,575
Anthony Mancini
See Remarks
Oct 26, 2026Sale(10b5-1 plan)−2,310$186.99$431.95K39,765
Anthony Mancini
See Remarks
Oct 26, 2026Option exercise+2,310$33.62$77.66K42,075
Alan B. Sandler
Chief Development Officer
Sep 29, 2026Sale(10b5-1 plan)−301$204.72$61.62K52,559
Alan B. Sandler
Chief Development Officer
Sep 29, 2026Sale(10b5-1 plan)−1,199$203.91$244.48K52,860
Alan B. Sandler
Chief Development Officer
Sep 29, 2026Sale(10b5-1 plan)−1,000$202.81$202.81K54,059
Alan B. Sandler
Chief Development Officer
Sep 29, 2026Sale(10b5-1 plan)−1,609$201.72$324.57K55,059
Alan B. Sandler
Chief Development Officer
Sep 29, 2026Sale(10b5-1 plan)−2,200$200.82$441.80K56,668
Alan B. Sandler
Chief Development Officer
Sep 29, 2026Option exercise+6,000$58.84$353.04K58,868
Jeff Cislini
SVP & General Counsel
Sep 25, 2026Sale(10b5-1 plan)−765$207.32$158.60K51,776
Anthony Mancini
See Remarks
Sep 25, 2026Option exercise+3,121$33.62$104.93K42,886
Anthony Mancini
See Remarks
Sep 25, 2026Sale(10b5-1 plan)−3,121$200.54$625.89K39,765
Anthony Mancini
See Remarks
Sep 24, 2026Sale(10b5-1 plan)−587$200.00$117.40K39,765
Elizabeth M. Anderson
Director
Sep 22, 2026Sale(10b5-1 plan)−1,500$194.59$291.89K4,433
Elizabeth M. Anderson
Director
Sep 22, 2026Option exercise+5,070$1.12$5.68K14,476
Elizabeth M. Anderson
Director
Sep 22, 2026Sale(10b5-1 plan)−910$191.85$174.58K13,566
Elizabeth M. Anderson
Director
Sep 22, 2026Sale(10b5-1 plan)−4,985$192.54$959.81K8,581
Elizabeth M. Anderson
Director
Sep 22, 2026Sale(10b5-1 plan)−2,648$193.44$512.23K5,933
Elizabeth M. Anderson
Director
Sep 22, 2026Sale(10b5-1 plan)−100$195.15$19.52K4,333
Anthony Mancini
See Remarks
Sep 18, 2026Sale(10b5-1 plan)−1,764$196.94$347.40K40,352
Jeff Cislini
SVP & General Counsel
Sep 16, 2026Sale(10b5-1 plan)−3,314$199.30$660.48K52,541
Jeff Cislini
SVP & General Counsel
Sep 16, 2026Sale(10b5-1 plan)−52$195.01$10.14K55,855
Alan B. Sandler
Chief Development Officer
Sep 16, 2026Sale(10b5-1 plan)−5$194.96$97553,204
Alan B. Sandler
Chief Development Officer
Sep 16, 2026Sale(10b5-1 plan)−336$199.30$66.96K52,868
Jack Anders
Chief Financial Officer
Sep 16, 2026Sale(10b5-1 plan)−61$195.00$11.90K123,208
Jack Anders
Chief Financial Officer
Sep 16, 2026Sale(10b5-1 plan)−3,992$199.30$795.61K119,216
Margaret A. Horn
Chief Operating Officer
Sep 16, 2026Sale(10b5-1 plan)−76$195.01$14.82K154,571
Margaret A. Horn
Chief Operating Officer
Sep 16, 2026Sale(10b5-1 plan)−4,891$199.30$974.78K149,680
Mark A. Goldsmith
See Remarks, Director
Sep 16, 2026Sale(10b5-1 plan)−13,775$199.30$2.75M253,342
Mark A. Goldsmith
See Remarks, Director
Sep 16, 2026Sale(10b5-1 plan)−213$195.01$41.54K267,117
Anthony Mancini
See Remarks
Sep 16, 2026Sale(10b5-1 plan)−27$195.05$5.27K43,863
Anthony Mancini
See Remarks
Sep 16, 2026Sale(10b5-1 plan)−1,747$199.30$348.18K42,116
Stephen Michael Kelsey
See Remarks
Sep 16, 2026Sale(10b5-1 plan)−5,484$199.30$1.09M286,307
Stephen Michael Kelsey
See Remarks
Sep 16, 2026Sale(10b5-1 plan)−85$195.01$16.58K291,791
Stephen Michael Kelsey
See Remarks
Sep 11, 2026Option exercise+40,031$40.74$1.63M384,407
Stephen Michael Kelsey
See Remarks
Sep 11, 2026Option exercise+52,500$42.45$2.23M344,376
Stephen Michael Kelsey
See Remarks
Sep 11, 2026Sale(10b5-1 plan)−800$198.55$158.84K383,607
Stephen Michael Kelsey
See Remarks
Sep 11, 2026Sale(10b5-1 plan)−11,833$200.11$2.37M371,774
Stephen Michael Kelsey
See Remarks
Sep 11, 2026Sale(10b5-1 plan)−13,368$200.78$2.68M358,406
Stephen Michael Kelsey
See Remarks
Sep 11, 2026Sale(10b5-1 plan)−21,447$201.75$4.33M336,959
Stephen Michael Kelsey
See Remarks
Sep 11, 2026Sale(10b5-1 plan)−18,869$203.06$3.83M318,090
Stephen Michael Kelsey
See Remarks
Sep 11, 2026Sale(10b5-1 plan)−17,949$203.87$3.66M300,141
Stephen Michael Kelsey
See Remarks
Sep 11, 2026Sale(10b5-1 plan)−4,995$204.84$1.02M295,146

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
13M shares short
Days to cover
7.8
At 2M shares a day
Change since last report
+1.1%
From 13M shares
Short volume, 20 days
55.7%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Revolution Medicines's stock actually held short. Settlement fails (shares not delivered on time) peaked at 462 shares on Sep 16, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Alan B. Sandler
Officer
Sep 29, 20266,309$1.27MSep 29, 2026Exercise of Stock Options
Anthony Mancini
Officer
Sep 25, 20269,363$1.87MSep 25, 2026Exercise of Stock Options
Anthony Mancini
Officer
Sep 24, 2026587$111.96KSep 24, 2026Restricted Stock Units
Elizabeth M. Anderson
Director
Sep 22, 202615,080$2.91MSep 22, 2026Exercise of Stock Options
Anthony Mancini
Officer
Sep 18, 20261,764$347.40KSep 18, 2026Restricted Stock Units
Alan B. Sandler
Officer
Sep 15, 2026331$67.45KSep 15, 2026RSU vesting
Anthony Mancini
Officer
Sep 15, 20262,377$484.36KSep 15, 2026RSU vesting
Stephen Michael Kelsey
Officer
Sep 15, 20265,415$1.10MSep 15, 2026RSU vesting
Margaret A. Horn
Officer
Sep 15, 20264,830$984.21KSep 15, 2026RSU vesting
Mark A. Goldsmith
Officer, Director
Sep 15, 202613,603$2.77MSep 15, 2026RSU vesting
Jeff Cislini
Officer
Sep 15, 20263,272$666.74KSep 15, 2026RSU vesting
Jack Anders
Officer
Sep 15, 20263,939$802.65KSep 15, 2026RSU vesting
Stephen Michael Kelsey
Officer
Sep 11, 202692,531$18.82MSep 11, 2026Exercise of Stock Options
Anthony Mancini
Officer
Sep 10, 202615,448$3.21MSep 10, 2026Exercise of Stock Options
Lorence H. Kim
Affiliate
Aug 31, 202673,090$15.19MAug 31, 2026Purchase

See a number that looks wrong?